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With Outcomes After Pediatric Cardiac Arrest
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for the Personalizing Outcomes After Child Cardiac Arrest (POCCA) Investigators

Abstract

Key Points

IMPORTANCE Families and clinicians have limited validated tools available to assist in estimating
long-term outcomes early after pediatric cardiac arrest. Blood-based brain-specific biomarkers may
be helpful tools to aid in outcome assessment.

Question Are early blood-based brain
injury biomarkers associated with an
unfavorable outcome 1 year after
pediatric cardiac arrest?

OBJECTIVE To analyze the association of blood-based brain injury biomarker concentrations with

Findings In this cohort study of 120

outcomes 1 year after pediatric cardiac arrest.

children who were resuscitated after
cardiac arrest, blood concentrations of 4

DESIGN, SETTING, AND PARTICIPANTS The Personalizing Outcomes After Child Cardiac Arrest

brain injury biomarkers (glial fibrillary

multicenter prospective cohort study was conducted in pediatric intensive care units at 14 academic

acidic protein, ubiquitin carboxyl-

referral centers in the US between May 16, 2017, and August 19, 2020, with the primary investigators

terminal esterase L1, neurofilament

blinded to 1-year outcomes. The study included 120 children aged 48 hours to 17 years who were

light, and tau) were associated with

resuscitated after cardiac arrest, had pre–cardiac arrest Pediatric Cerebral Performance Category

unfavorable outcomes at 1 year.

scores of 1 to 3 points, and were admitted to an intensive care unit after cardiac arrest.

Meaning These findings suggest that
blood-based brain injury biomarkers for

EXPOSURE Cardiac arrest.

clinical use may aid in early outcome
assessment after pediatric

MAIN OUTCOMES AND MEASURES The primary outcome was an unfavorable outcome (death or

cardiac arrest.

survival with a Vineland Adaptive Behavior Scales, third edition, score of <70 points) at 1 year after
cardiac arrest. Glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal esterase L1 (UCH-L1),
neurofilament light (NfL), and tau concentrations were measured in blood samples from days 1 to 3
after cardiac arrest. Multivariate logistic regression and area under the receiver operating
characteristic curve (AUROC) analyses were performed to examine the association of each biomarker
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Author affiliations and article information are
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with outcomes on days 1 to 3.
RESULTS Among 120 children with primary outcome data available, the median (IQR) age was 1.0
(0-8.5) year; 71 children (59.2%) were male. A total of 5 children (4.2%) were Asian, 19 (15.8%) were
Black, 81 (67.5%) were White, and 15 (12.5%) were of unknown race; among 110 children with data
on ethnicity, 11 (10.0%) were Hispanic, and 99 (90.0%) were non-Hispanic. Overall, 70 children
(58.3%) had a favorable outcome, and 50 children (41.7%) had an unfavorable outcome, including 43
deaths. On days 1 to 3 after cardiac arrest, concentrations of all 4 measured biomarkers were higher
in children with an unfavorable vs a favorable outcome at 1 year. After covariate adjustment, NfL
concentrations on day 1 (adjusted odds ratio [aOR], 5.91; 95% CI, 1.82-19.19), day 2 (aOR, 11.88; 95%
CI, 3.82-36.92), and day 3 (aOR, 10.22; 95% CI, 3.14-33.33); UCH-L1 concentrations on day 2 (aOR,
11.27; 95% CI, 3.00-42.36) and day 3 (aOR, 7.56; 95% CI, 2.11-27.09); GFAP concentrations on day 2
(aOR, 2.31; 95% CI, 1.19-4.48) and day 3 (aOR, 2.19; 95% CI, 1.19-4.03); and tau concentrations on day
(continued)
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Abstract (continued)

1 (aOR, 2.44; 95% CI, 1.14-5.25), day 2 (aOR, 2.28; 95% CI, 1.31-3.97), and day 3 (aOR, 2.04; 95% CI,
1.16-3.57) were associated with an unfavorable outcome. The AUROC models were significantly
higher with vs without the addition of NfL on day 2 (AUROC, 0.932 [95% CI, 0.877-0.987] vs 0.871
[95% CI, 0.793-0.949]; P = .02) and day 3 (AUROC, 0.921 [95% CI, 0.857-0.986] vs 0.870 [95% CI,
0.786-0.953]; P = .03).
CONCLUSIONS AND RELEVANCE In this cohort study, blood-based brain injury biomarkers,
especially NfL, were associated with an unfavorable outcome at 1 year after pediatric cardiac arrest.
Additional evaluation of the accuracy of the association between biomarkers and
neurodevelopmental outcomes beyond 1 year is needed.
JAMA Network Open. 2022;5(9):e2230518. doi:10.1001/jamanetworkopen.2022.30518

Introduction
Approximately 10 000 children experience in-hospital or out-of-hospital cardiac arrest annually in
the US.1,2 Children with return of spontaneous circulation (ROSC) are at high risk of neurological
morbidity and death due to global hypoxic-ischemic brain injury.3 Accurate early understanding of
the risk of neurological injury could support clinician and family decision-making and treatment.
However, a standardized validated approach is lacking.4
Small observational studies have found that blood-based brain injury biomarkers may be
associated with outcomes after pediatric cardiac arrest.5,6 The brain-specific biomarkers ubiquitin
carboxyl-terminal esterase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) have been approved
by the US Food and Drug Administration to assist in clinical decision-making for mild traumatic brain
injury in adults and differentiated outcomes in a pilot study of pediatric cardiac arrest.7-9 The UCH-L1
enzyme, which is located in neurons, normally participates in the degradation of damaged proteins,10
and GFAP forms intermediate filaments that support the shape and function of astroglia cells.11
Furthermore, biomarkers of blood-based white matter injury are helpful tools after pediatric and
adult cardiac arrest.12,13 Thus, neurofilament light (NfL), a component of the neuronal cytoskeleton
providing structural support to axons,14-16 and tau, a microtubule-stabilizing neuroaxial protein that
maintains stability of axon microtubules, were also included in this study.17,18
We conducted a prospective multicenter cohort study (Personalizing Outcomes After Child
Cardiac Arrest [POCCA]) to evaluate the association of these 4 brain-specific biomarkers on days 1 to
3 after pediatric cardiac arrest with the composite outcome of death or unfavorable adaptive
behavior at 1 year. We hypothesized that each blood-based biomarker would be associated with
outcomes after cardiac arrest.

Methods
Study Design and Setting
The POCCA prospective cohort study was conducted in pediatric intensive care units (ICUs) at 14
academic referral centers in the US between May 16, 2017, and August 19, 2020, with follow-up
through 1 year after enrollment. The institutional review board of the University of Pittsburgh served
as the study’s central review board and approved the study for performance at UPMC Children’s
Hospital of Pittsburgh. Two sites, Children’s Healthcare of Atlanta and Children’s Wisconsin, obtained
independent institutional review board approval because they were unable to participate in the
central review board. Written informed consent from a parent or guardian was required for
participation, and written patient assent was obtained when appropriate (based on local center
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guidelines). This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for cohort studies.19

Participants
Eligible children were aged 48 hours to 17 years, had chest compressions performed for any duration
of time for in-hospital or out-of-hospital events, and had a pre–cardiac arrest score of 1 to 3 points on
the Pediatric Cerebral Performance Category scale (score range, 1-6 points, with 1 indicating good, 2
indicating mild disability, 3 indicating moderate disability, 4 indicating severe disability, 5 indicating
vegetative state, and 6 indicating death).20 Children were excluded if they had a do-not-resuscitate
order or were actively undergoing brain death evaluation at the time of screening, were in foster care
or the judicial system, were pregnant, or did not have a blood sample (200 μL) available within 24
hours of cardiac arrest. Screening occurred daily. Patients did not receive any study-related
treatment interventions. Clinical care was provided by the patient’s clinical team.
Among 932 children who experienced a cardiac arrest, 859 were assessed for eligibility.
Children could have met 1 or more criteria that made them ineligible for participation. A total of 506
children were ineligible, with the most frequent criteria being lack of a blood sample within the first
24 hours after ROSC (143 patients [28.3%]), a pre–cardiac arrest Pediatric Cerebral Performance
Category score of 4 points (indicating severe neurological disability) and/or 5 points (indicating coma;
125 patients [24.7%]), initiation of brain death evaluation (90 patients [17.8%]), and/or care
limitations (81 patients [16.0%]). Among the remaining 353 children eligible for participation, 102
families (28.9%) declined consent, 87 families (24.6%) were not approached for consent, and 164
families (46.5%) provided informed consent; of those who provided consent, 44 children (26.8%)
did not have primary outcome data available (39 children were unavailable for follow-up, and 5
families withdrew consent; 1 of the families who withdrew consent requested the child’s data be
removed, resulting in 43 of 163 children [26.4%] without primary outcome data available). A total of
120 children with primary outcome data were included in the final study sample (Figure 1).

Data Collection
Data were collected locally using a case report form. Cardiac arrest, resuscitation, and post-ROSC
variables were collected from the medical record using Utstein definitions.21,22 Patient demographic
characteristics were extracted from the medical record using categories recommended by the
National Institutes of Health.23 Organ support, testing results, and some outcomes were collected
from the medical record. Cause of death was abstracted from the death certificate. The score on the
Pediatric Index of Mortality 3 (score range, 0-100, with higher scores indicating higher risk of death)
was recorded using the first value of each variable measured from the ICU admission to 1 hour after
arrival in the ICU or, for cardiac arrests occurring in the ICU, the score was recorded using the first
value within 1 hour after ROSC.24
Blood-Based Biomarkers
Three milliliters of blood was collected prospectively on days 1 to 3 after ROSC. Day 1 was defined as
the first 24 hours after ROSC, day 2 as 24 to 48 hours after ROSC, and day 3 as 48 to 72 hours after
ROSC. Blood samples were centrifuged, aliquoted, frozen at −70 °C, and mailed to the University of
Pittsburgh for storage and batched analysis. If prospective samples were not available, leftover
serum or plasma could be obtained from the hospital’s laboratory and stored and mailed using the
same procedure. Concentrations of NfL, UCH-L1, GFAP, and tau in serum or plasma were measured
by a laboratory technician at an independent laboratory (Quanterix) using an assay specific to the 4
biomarkers of interest (Simoa Human Neurology 4-Plex A; Quanterix); the technician was blinded
to patient data. Lower limits of quantitation from the assay were 0.241 pg/mL for NfL, 5.450 pg/mL
for UCH-L1, 0.467 pg/mL for GFAP, and 0.053 pg/mL for tau. Samples were measured in duplicate;
mean concentrations were used for analysis. Dilution factors of 4, 10, or 1000 were used. Clinical
team members were blinded to the biomarker results. One child’s family withdrew all data, and
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another child did not have a blood sample available on day 1, leaving 162 samples for analysis. On
days 2 and 3, samples were available from 141 patients and 128 patients, respectively.

Outcome Measures
Patient follow-up was performed by each center. Parents or guardians completed the Vineland
Adaptive Behavior Scales, third edition (VABS-3), rating form at 1 year via in-person, mail, or
telephone follow-up.25 The VABS-3 is a standardized measure of adaptive behavior function based on
caregiver report. The VABS-3 provides age-corrected standard scores (mean [SD], 100 [15] points)
for individuals from birth through age 90 years in 4 domains (communication, daily living,
socialization, and motor skills) and an overall adaptive behavior composite score, with higher scores
denoting better functioning. A favorable outcome was defined as survival with a VABS-3 overall
adaptive behavior composite score of 70 points or greater, and an unfavorable outcome was defined
as a VABS-3 overall adaptive behavior composite score lower than 70 points or death, consistent with
previous studies of children with cardiac arrest.26,27 Questionnaire responses were evaluated for
quality and reliability by the primary study team.

Statistical Analysis
A sample size of 164 patients achieved 80% power to detect an R2 of 0.10 for 15 independent
variables (various combinations of trajectory groups with varying numbers of trajectories) using an F
test with a significance threshold of α = .05. The variables tested were adjusted for an additional 2
independent variables, with an R2 of 0.10.9

Figure 1. Study Flowchart
859 Children assessed for eligibility
506 Ineligible (657 reasons for ineligibility)a
143 Did not have blood sample available
125 Had baseline PCPC score of 4 or 5
90 Had brain death examination initiated
81 Had support limitations
62 Did not speak English
42 Were in foster care or judicial system
41 Were aged <48 h or >17 y
35 Did not have true cardiac arrest after
further examination
11 Were unsuitable for inclusion per PI
9 Did not have parent or guardian available
8 Were not expected to surviveb
7 Were not in ICU
2 Had repeat cardiac arrest during
same admission
1 Was previously enrolled in the study
353 Eligible for inclusion
189 Did not consent to participate in studyc
102 Declined consent
87 Not approached for consent
164 Consented to participate in studyc
44 Did not have primary outcome data available
39 Were unavailable for follow-up
5 Withdrew consent

ICU indicates intensive care unit; PCPC, Pediatric
Cerebral Performance Category; PI, primary
investigator; and VABS-3, Vineland Adaptive Behavior
Scales, third edition.
a

Children may have met 1 or more criteria that made
them ineligible for the study.

b

Criteria regarding likelihood of survival were
determined by site research personnel; therefore, it
was inappropriate to approach these patients for
enrollment.

c

Informed consent from a parent or guardian was
required for participation, and patient assent was
obtained when appropriate.

120 Had primary outcome data available at 1 y

50 Had unfavorable outcomes
43 Died
7 Had VABS-3 score <70

70 Had favorable outcomes
70 Had VABS-3 score ≥70
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Frequencies and percentages were reported for categorical variables. Biomarker data were log
transformed and presented as medians with IQRs owing to nonparametric distributions. All patient
and cardiac arrest variables were first evaluated as univariates for inclusion in the multivariate
analysis28 using χ2 or Kruskal-Wallis tests as appropriate to examine the associations of
characteristics and clinical features with 1-year outcomes. Covariates considered in the multivariate
models included age, sex, race, ethnicity, preexisting conditions, cardiac arrest etiology, cardiac arrest
location, duration of cardiopulmonary resuscitation, epinephrine boluses and defibrillations, first
monitored rhythm, witnessed event status (a cardiac arrest that was seen or heard by another person
or a cardiac arrest that was monitored22), bystander resuscitation (nonhospital personnel or hospital
personnel not part of the emergency response system22), extracorporeal membrane oxygenation
use, first blood pH and lactate levels, Pediatric Index of Mortality 3 score, first ICU Glasgow Coma
Scale overall score (score range, 3-15 points, with higher scores indicating higher level of
consciousness) and subscale scores (eye opening, verbal response, and motor response), and
targeted temperature management (TTM) for fever prevention or therapeutic hypothermia.
Covariates that were significant at P ⱕ .20 were then evaluated using multivariable logistic
regression models with stepwise selection and entry and removal levels of 0.20. We forced the
inclusion of the log of the biomarker concentrations. Models were performed separately for each
biomarker.
A multivariable analysis of the area under the receiver operating characteristic curve (AUROC)
was used to assess the accuracy of each biomarker at each day by comparing the final logistic
regression models with and without each biomarker among those who had unfavorable outcomes at
1 year. The threshold for statistical significance was 2-sided P < .05. Biomarker specificity, threshold
(in picograms per milliliter), and sensitivity on univariate biomarker models were measured with a set
specificity of 95% to minimize the chance of false assignment of an unfavorable outcome.
Missing data were not imputed. Only patients with primary outcome data available were
analyzed. All analyses were conducted using SAS software, version 9.2 (SAS Institute, Inc).

Results
Participants
Of 120 children with primary outcome data available at 1 year, the median (IQR) age was 1.0 (0-8.5)
year; 49 children (40.8%) were female, and 71 (59.2%) were male. A total of 5 children (4.2%) were
Asian, 19 (15.8%) were Black, 81 (67.5%) were White, and 15 (12.5%) were of unknown race; of 110
children with data on ethnicity, 11 (10.9%) were Hispanic, and 99 (90.0%) were non-Hispanic.
Patient characteristics, including race and ethnicity, were not different by outcome (Table 1).
Compared with children who had a favorable outcome, those with an unfavorable outcome more
frequently had out-of-hospital cardiac arrest (35 children [70.0%] vs 25 children [35.7%]), longer
duration of cardiopulmonary resuscitation (median [IQR], 20.0 [6.0-40.0] minutes vs 5.0 [2.0-11.0]
minutes), and an unwitnessed event (23 children [46.0%] vs 5 children [7.1%]) (Table 2).
Among all 120 children, 79 children (65.8%) survived. Of the 43 children who died, 2 died after
hospital discharge and before 1 year. Of those who survived, 70 children (88.6%) had a favorable
outcome, and 9 (11.4%) had an unfavorable outcome. Thus, overall, 70 children (58.3%) had a
favorable outcome, and 50 (41.7%) had an unfavorable outcome.

Postresuscitation Data and Outcomes
Almost all children (117 patients [97.5%]) received mechanical ventilation, and vasoactive infusions
were frequently used after ROSC (158 total infusions, with most children receiving epinephrine [76
infusions]) (eTable 1 in Supplement 1). Extracorporeal membrane oxygenation was used in 28
children (23.3%), with extracorporeal cardiopulmonary resuscitation representing most indications
(22 children [78.6%]). Targeted temperature management to prevent fever was used more
frequently in children with unfavorable vs favorable outcomes (18 children [36.0%] vs 12 children
JAMA Network Open. 2022;5(9):e2230518. doi:10.1001/jamanetworkopen.2022.30518 (Reprinted)
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[17.1%]; P = .03), whereas TTM for therapeutic hypothermia was used in 12 children (17.1%) with a
favorable outcome vs 3 children (6.0%; P = .07) with an unfavorable outcome.

Blood Biomarker Concentrations by Outcome Group
Biomarker concentrations by outcome group on days 1, 2, and 3 after cardiac arrest are shown as
picogram per milliliter concentrations in eTable 2 in Supplement 1 and as log-transformed
concentrations in Figure 2. Biomarker concentrations were higher in children with unfavorable vs
favorable 1-year outcomes for each of the 4 biomarkers studied. For example, on day 1, median (IQR)
concentrations in the unfavorable vs favorable outcome groups were 50.54 (20.56-169.00) pg/mL
vs 13.81 (6.29-49.98) pg/mL (P < .001) for NfL, 310.40 (110.73-848.36) pg/mL vs 73.39
(25.36-230.77) pg/mL (P < .001) for UCH-L1, 469.88 (137.70-2780.48) pg/mL vs 174.85
(79.63-401.27) pg/mL (P = .002) for GFAP, and 50.10 (6.53-149.30) pg/mL vs 5.59 (1.89-18.85)
pg/mL (P < .001) for tau.

AUROCs, Sensitivity, and Specificity of Biomarkers by Outcome Group
Univariate AUROCs for the outcome of individual biomarkers at days 1 to 3 are shown in eTable 3 in
Supplement 1. On day 1, NfL had the best accuracy for 1-year outcome (AUROC, 0.731; 95% CI,
0.642-0.820), improving to 0.824 (95% CI, 0.742-0.907) on day 3. The best accuracy for 1-year
outcome on day 2 (AUROC, 0.860; 95% CI, 0.785-0.935) and day 3 (AUROC, 0.837; 95% CI, 0.7470.926) was observed for UCH-L1.
Biomarker sensitivity and threshold values selected to minimize false-positive identification of
unfavorable outcomes for each day are shown in eTable 3 in Supplement 1. On all study days, 3
children were falsely classified as having an unfavorable outcome based on all 4 biomarkers, with the
exception of day 2, during which UCH-L1 false-positive results occurred for 2 children. When
purposely fixing specificity to 95%, tau had the best sensitivity of the 4 biomarkers on day 1 (AUROC,

Table 1. Patient Characteristics Overall and by Outcome Group
Patients, No./total No. (%)
Characteristic

Overall
(N = 120)

Favorable outcome
(n = 70)a

Unfavorable outcome
(n = 50)b

P valuec

Age, median (IQR), y

1.0 (0-8.5)

1.0 (0-9.0)

1.0 (0-6.0)

.55

Female

49/120 (40.8)

28/70 (40.0)

21/50 (42.0)

Male

71/120 (59.2)

42/70 (60.0)

29/50 (58.0)

Asian

5/120 (4.2)

2/70 (2.9)

3/50 (6.0)

Black

19/120 (15.8)

12/70 (17.1)

7/50 (14.0)

White

81/120 (67.5)

46/70 (65.7)

35/50 (70.0)

Unknown

15/120 (12.5)

10/70 (14.3)

5/50 (10.0)

Sex
.83

Race

.71

Ethnicity
Hispanic

11/110 (10.0)

6/63 (9.5)

5/47 (10.6)

Non-Hispanic

99/110 (90.0)

57/63 (90.5)

42/47 (89.4)

d

.85

77/113 (68.1)

44/63 (69.8)

33/50 (66.0)

.66

Cardiovascular

45/119 (37.8)

27/69 (39.1)

18/50 (36.0)

.73

Congenital

14/119 (11.8)

8/69 (11.6)

6/50 (12.0)

.95

Premature birth

24/110 (21.8)

18/62 (29.0)

6/48 (12.5)

.04

Neurological

11/120 (9.2)

5/70 (7.1)

6/50 (12.0)

.36

Pulmonary

25/120 (20.8)

14/70 (20.0)

11/50 (22.0)

.79

Cancer

3/120 (2.5)

2/70 (2.9)

1/50 (2.0)

.77

Organ or cell transplant

3/119 (2.5)

1/69 (1.4)

2/50 (4.0)

.38

Other

11/119 (9.2)

3/69 (4.3)

8/50 (16.0)

.03

Preexisting conditions
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A favorable outcome was defined as a Vineland
Adaptive Behavior Scales, third edition (VABS-3),
score of ⱖ70 points.

b

An unfavorable outcome was defined as a VABS-3
score of <70 points or death.

c

P values are based on a χ2 test for categorical
variables and a Kruskal-Wallis test for continuous
variables.

d

Patients may have had more than 1 preexisting
condition.
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0.333; 95% CI, 0.204-0.484), and UCH-L1 had the best sensitivity on day 2 (AUROC, 0.581; 95% CI,
0.421-0.730) and day 3 (AUROC, 0.605; 95% CI, 0.434-0.760).

Multivariate Logistic Regression and AUROC Analyses of Unfavorable Outcome
For each day, multivariate logistic regression analyses were performed for individual biomarkers to
assess their association with 1-year outcomes, with adjustment for patient and clinical covariates
(Table 3; eTable 4 in Supplement 1). Concentrations of the following biomarkers were associated with
unfavorable 1-year outcomes: NfL on post–cardiac arrest day 1 (adjusted odds ratio [aOR], 5.91; 95%
CI, 1.82-19.19), day 2 (aOR, 11.88; 95% CI, 3.82-36.92), and day 3 (aOR, 10.22; 95% CI, 3.14-33.33;
UCH-L1 on day 2 (aOR, 11.27; 95% CI, 3.00-42.36) and day 3 (aOR, 7.56 ; 95% CI, 2.11-27.09); GFAP on
day 2 (aOR, 2.31; 95% CI, 1.19-4.48) and day 3 (aOR, 2.19; 95% CI, 1.19-4.03); and tau on day 1 (aOR,
2.44; 95% CI, 1.14-5.25), day 2 (aOR, 2.28; 95% CI, 1.31-3.97), and day 3 (aOR, 2.04; 95% CI,
1.16-3.57). The covariates most frequently associated with unfavorable outcomes across the
multivariate models were unwitnessed events (eg, aORs for witnessed events on day 1: 0.15 [95% CI,
0.03-0.84] for NfL, 0.14 [95% CI, 0.03-0.81] for UCH-L1, 0.17 [95% CI, 0.03-0.91] for GFAP, and 0.11
[95% CI, 0.02-0.71] for tau), higher Pediatric Index of Mortality 3 score (eg, aORs on day 1: 2.47 [95%
CI, 1.54-3.97] for NfL, 2.29 [95% CI, 1.44-3.64] for UCH-L1, 2.47 [95% CI, 1.56-3.90] for GFAP, and

Table 2. Cardiac Arrest, Resuscitation, Post–Cardiac Arrest, and Overall Outcomes at 1 Year
After Cardiac Arrest by Outcome Group
Patients, No./total No. (%)
Overall
(N = 120)

Favorable
outcome (n = 70)a

Unfavorable
outcome (n = 50)b

Asphyxia

74/107 (69.2)

45/66 (68.2)

29/41 (70.7)

Cardiac

33/107 (30.8)

21/66 (31.8)

12/41 (29.3)

Variable

P valuec

Primary etiology
.78

Location out of hospital

60/120 (50.0)

25/70 (35.7)

35/50 (70.0)

<.001

Duration of cardiopulmonary resuscitation,
median (IQR), mind

7.0 (3.0-20.0)

5.0 (2.0-11.0)

20.0 (6.0-40.0)

<.001

Epinephrine doses, median (IQR)e

1.0 (0-4.0)

1.0 (0-3.0)

2.5 (1.0-5.0)

.04

Received defibrillation

18/101 (17.8)

11/61 (18.0)

7/40 (17.5)

.94

First monitored rhythm
Sinus bradycardia

33/96 (34.4)

23/58 (39.7)

10/38 (26.3)

Pulseless electrical activity

23/96 (24.0)

14/58 (24.1)

9/38 (23.7)

Asystole

19/96 (19.8)

7/58 (12.1)

12/38 (31.6)

Ventricular tachycardia or fibrillation

15/96 (15.6)

10/58 (17.2)

5/38 (13.2)

Otherf

6/96 (6.3)

4/58 (6.9)

2/38 (5.3)

Event witnessed

92/120 (76.7)

65/70 (92.9)

27/50 (54.0)

<.001

Bystander resuscitation

42/120 (35.0)

17/70 (24.3)

25/50 (50.0)

.004

Hospital length of stay, median (IQR), d

18.0 (6.5-35.5)

20.5 (10.0-41.0)

12.0 (5.0-34.0)

.09

ICU length of stay, median (IQR), dg

12.0 (5.0-25.0)

14.0 (6.0-21.0)

11.0 (5.0-31.5)

.78

55/120 (45.8)

50/70 (71.4)

5/50 (10.0)

.04
Abbreviations: ICU, intensive care unit; NA, not
applicable.
a

A favorable outcome was defined as a Vineland
Adaptive Behavior Scales, third edition (VABS-3),
score of ⱖ70 points.

b

An unfavorable outcome was defined as a VABS-3
score of <70 points or death.

c

P values are based on a χ2 test for categorical
variables and a Kruskal-Wallis test for continuous
variables.

d

Among 98 patients (64 with favorable outcomes and
34 with unfavorable outcomes).

e

Among 100 patients (60 with favorable outcomes
and 40 with unfavorable outcomes).

f

Normal sinus, sinus tachycardia, and junctional
ectopic tachycardia.

g

Among 117 patients (69 with favorable outcomes and
48 with unfavorable outcomes).

h

Among 43 patients (43 with unfavorable outcomes).

i

Per death certificate.

Disposition at hospital discharge
Home
Died

41/120 (34.2)

0

41/50 (82.0)

Inpatient rehabilitation

17/120 (14.2)

15/70 (21.4)

2/50 (4.0)

Transfer to other hospital

2/120 (1.7)

2/70 (2.9)

0

Long-term care facility
Days from cardiac arrest to death,
median (IQR)h

5/120 (4.2)

3/70 (4.3)

2/50 (4.0)

10 (3-25)

NA

10 (3-25)

<.001

NA

Cause of deathi
Multiple organ failure

13/43 (30.2)

NA

13/43 (30.2)

Brain death

11/43 (25.6)

NA

11/43 (25.6)

Neurologic injury

11/43 (25.6)

NA

11/43 (25.6)

Cardiovascular

8/43 (18.6)

NA

8/43 (18.6)

NA
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2.10 [95% CI, 1.35-3.26] for tau), and lack of TTM for hypothermia (eg, aORs for use of TTM for
therapeutic hypothermia on day 1: 0.02 [95% CI, 0-0.76] for NfL, 0.02 [95% CI, 0.001-0.37] for
UCH-L1, 0.02 [95% CI, 0.001-0.38] for GFAP, and 0.02 [95% CI, 0.001-0.53] for tau) (Table 3).
Multivariate AUROCs for outcomes with and without individual biomarkers for days 1 to 3 are shown
in eTable 5 in Supplement 1. The models were significantly higher with vs without the addition of NfL
for day 2 (AUROC, 0.932 [95% CI, 0.877-0.987] vs 0.871 [95% CI, 0.793-0.949]; P = .02) and day 3
(AUROC, 0.921 [95% CI, 0.857-0.986] vs 0.870 [95% CI, 0.786-0.953]; P = .03).

Discussion
To our knowledge, this cohort study is the largest analysis to date of the association between
prospective blood-based brain injury biomarker concentrations and pediatric cardiac arrest. Results
revealed that each of the 4 blood-based brain injury biomarkers that were analyzed early in the post–
cardiac arrest period discriminated between favorable and unfavorable 1-year outcomes with high
accuracy.29 These results remained significant after adjustment for common clinical factors

Figure 2. Log-Transformed Biomarker Concentrations Overall and by Outcome Group
A Neurofilament light

B

5
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Glial fibrillary acidic protein
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C

Day 2

Time after cardiac arrest
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3

2

1
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–1
Day 1

Day 2

Day 3

Day 1
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The Vineland Adaptive Behavior Scales, third edition (VABS-3) provides age-corrected
standard scores (mean [SD], 100 [15] points) for individuals from birth through age 90
years in 4 domains (communication, daily living, socialization, and motor skills) and an
overall adaptive behavior composite score, with higher scores denoting better
functioning. A favorable outcome was defined as a VABS-3 overall adaptive behavior
composite score of ⱖ70 points, and an unfavorable outcome was defined as a VABS-3

Day 2

Day 3

Time after cardiac arrest

overall adaptive behavior composite score of <70 points or death. P < .001 for each
comparison (with the exception of GFAP on day 1 [P = .002]) using a Kruskal-Wallis test.
Circles represent outlier data points, diamonds represent statistically significant
associations, and whiskers represent 95% CIs. GFAP indicates glial fibrillary acidic
protein; NfL, neurofilament light; UCH-L1, ubiquitin carboxyl-terminal esterase L1.
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associated with outcomes, including unwitnessed event status and risk of death score at
admission.30
The NfL and UCH-L1 biomarkers both had high overall accuracy (based on the univariate AUROC
analysis) and reliability (over the period examined) for 1-year outcomes. Only NfL had significant
implications for multivariate AUROCs on days 2 and 3. Concentrations of NfL in children with both
favorable and unfavorable outcomes numerically increased over the study days, potentially
representing ongoing neuroaxonal injury.31,32 Our data are consistent with a single-center study15
involving children with cardiac arrest who experienced acute respiratory distress syndrome; that
study found that NfL was associated with unfavorable outcomes at hospital discharge (as measured
by Pediatric Cerebral Performance Category scores at discharge). A multicenter study16 that
examined biobank samples from 717 adults with cardiac arrest who participated in a randomized
clinical trial also found that NfL concentration was the best-performing biomarker compared with
neuron-specific enolase, S100 calcium-binding protein B, and tau for the assessment of unfavorable
outcomes based on the Cerebral Performance Category Scale at 6 months. Another study33 reported

Table 3. Stepwise Multivariate Logistic Regression Analysis of 1-Year Favorable vs Unfavorable Outcomes
on Days 1-3 After Cardiac Arrest by Biomarkera
aOR (95% CI)b
Biomarker

Day 1

Day 2

Day 3

Concentration, log pg/mL

5.91 (1.82-19.19)

11.88 (3.82-36.92)

10.22 (3.14-33.33)

Age

0.90 (0.79-1.04)

NA

NA

Male vs female sex

0.35 (0.10-1.23)

0.67 (0.20-2.31)

NA

Cardiac vs asphyxia etiology

2.55 (0.70-9.34)

NA

1.96 (0.50-7.68)

Event witnessed

0.15 (0.03-0.84)

NA

NA

PIM-3 score

2.47 (1.54-3.97)

2.09 (1.39-3.14)

1.92 (1.29-2.86)

TTM used for therapeutic hypothermia

0.02 (0-0.76)

0.04 (0.002-0.70)

0.08 (0.004-1.55)

Concentration, log pg/mL

2.01 (0.84-4.84)

11.27 (3.00-42.36)

7.56 (2.11-27.09)

Age

0.90 (0.79-1.01)

0.91 (0.79-1.04)

0.89 (0.76-1.05)

Neurofilament light

Ubiquitin carboxyl-terminal esterase L1

Male vs female sex

0.30 (0.09-1.01)

NA

0.56 (0.14-2.29)

Cardiac vs asphyxia etiology

2.61 (0.76-8.95)

NA

2.00 (0.47-8.54)

Event witnessed

0.14 (0.03-0.81)

0.09 (0.01-0.67)

0.11 (0.01-0.94)

PIM-3 score

2.29 (1.44-3.64)

1.44 (0.93-2.21)

1.56 (0.97-2.49)

TTM used for therapeutic hypothermia

0.02 (0.001-0.37)

0.02 (0.001-0.62)

0.02 (0.001-0.83)

Concentration, log pg/mL

1.36 (0.72-2.59)

2.31 (1.19-4.48)

2.19 (1.19-4.03)

Age

0.88 (0.79-0.99)

0.90 (0.79-1.02)

0.92 (0.81-1.04)

Male vs female sex

0.30 (0.09-0.98)

0.30 (0.08-1.09)

0.48 (0.15-1.60)

Cardiac vs asphyxia etiology

3.31 (0.94-11.65)

3.82 (0.94-15.58)

NA

Event witnessed

0.17 (0.03-0.91)

0.15 (0.03-0.87)

0.13 (0.02-0.69)

PIM-3 score

2.47 (1.56-3.90)

1.96 (1.23-3.11)

1.71 (1.13-2.58)

TTM used for prevention of fever

NA

NA

1.48 (0.42-5.18)

TTM used for therapeutic hypothermia

0.02 (0.001-0.38)

2.31 (1.19-4.48)

0.05 (0.003-0.92)

Concentration, log pg/mL

2.44 (1.14-5.25)

2.28 (1.31-3.97)

2.04 (1.16-3.57)

Age

0.90 (0.80-1.02)

0.93 (0.83-1.04)

0.97 (0.87-1.10)

Male vs female sex

0.24 (0.07-0.87)

0.53 (0.16-1.73)

0.58 (0.19-1.79)

Cardiac vs asphyxia etiology

2.25 (0.65-7.84)

NA

NA

Event witnessed

0.11 (0.02-0.71)

0.14 (0.03-0.68)

NA

PIM-3 score

2.10 (1.35-3.26)

1.79 (1.19-2.68)

1.87 (1.27-2.75)

Glial fibrillary acidic protein

Tau

TTM used for prevention of fever

NA

NA

1.90 (0.59-6.14)

TTM used for therapeutic hypothermia

0.02 (0.001-0.53)

0.06 (0.004-0.72)

0.16 (0.02-1.17)
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that the accuracy of NfL was better in adults (AUROC, 0.94-0.95 within the first 3 days after cardiac
arrest) compared with the children in our study, which could reflect differences associated with
patient developmental status, cardiac arrest phenotype, and/or patient selection. All patients in the
adult clinical trial33 had an out-of-hospital cardiac arrest and presumed cardiac etiology and were
comatose at the time of recruitment, whereas our study criteria were intentionally broad, with the
aim of assessing biomarker performance across a heterogeneous cohort (eg, out-of-hospital and
in-hospital cardiac arrest, asphyxia, and cardiac etiology) of children surviving to ICU admission
(without known care limitations) to achieve greater generalizability and support biomarker
translation into general clinical practice.
The UCH-L1 and GFAP biomarkers, both of which were approved by the Food and Drug
Administration for use in clinical decision-making among those with mild traumatic brain injury, had
the highest accuracy for 1-year outcomes on days 2 and 3 after cardiac arrest, replicating the findings
reported in a pilot study.7,8 The UCH-L1 biomarker had the highest sensitivity of the 4 biomarkers
when optimizing specificity on days 2 and 3. Notably, median UCH-L1 concentrations remained
unchanged in both outcome groups over the 3 days, whereas GFAP concentrations increased in
patients with unfavorable outcomes over the study period. A possible reason for this increase in
GFAP levels is the fact that GFAP is both released and induced by injured and/or dying astrocytes.23
For some biomarkers, dynamic trajectories may offer more information than a single time point.34
Our study has several clinical implications. First, although most surviving children had a
favorable 1-year outcome according to VABS-3 scores, they remained at risk of cognitive
dysfunction.35 Children may not be neurologically assessable on examination early after resuscitation
because of the need for sedative or neuromuscular blockade medications.36 The primary goal of the
POCCA study was to provide clinicians and families with early and accurate tests to assist in clinical
decision-making. Testing results can be used to facilitate discussion regarding planning for
rehabilitative needs or determining goals of care and use of technological support.9 We found that
blood-based brain injury biomarker testing, especially testing of NfL, was an accurate method to use
when considering the odds of a child’s unfavorable composite outcome of death or unfavorable
adaptive behavior function at 1 year in multivariate modeling. Our findings, as well as those of other
groups,15,16 could support blood-based biomarker translation into pediatric clinical practice. In
addition, these biomarkers could be used as a tool for estimation of enrichment in clinical trials if
applied to identify patients who are most or least likely to benefit from a neuroprotective
intervention. The biomarkers may also serve as surrogate outcomes to evaluate responsiveness to
interventions.37,38 Future directions for research include testing blood-based brain injury biomarkers
together and in combination with other clinical variables (eg, unwitnessed events, Pediatric Index of
Mortality 3 score, and TTM) and tests (eg, brain imaging) to identify clinical phenotypes associated
with outcomes that may be useful in future precision interventional clinical trials.39-41 In addition,
assessment of the associations of early blood-based brain injury biomarkers with longitudinal
neurodevelopmental and neuropsychological outcomes is needed.

Limitations
This study has several limitations. Most children were ineligible for the study because they did not
have a blood sample available within the first 24 hours after ROSC (28.3%), had a pre–cardiac arrest
Pediatric Cerebral Performance Category score of 4 points (indicating severe neurological disability)
and/or 5 points (indicating coma; 24.7%), were undergoing brain death evaluation (17.8%), and/or
had care limitations (16.0%). A total of 28.9% of families in our study declined consent compared
with those who declined consent in large out-of-hospital (27%) and in-hospital (55%) clinical
trials.26,27 The patient sample size decreased over days 2 to 3 because of deaths and lack of blood
samples. Biomarker concentrations were measured in the first 3 days; however, obtaining later blood
samples, alone and together with other biomarkers and clinical variables, may improve accuracy. Our
biomarker sampling strategy was pragmatic, acknowledging the need to prevent additional blood
sample collection for safety (eg, surplus laboratory samples and risk of infection because of
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in-dwelling catheters). Biomarkers were measured by a private company using proprietary assays
because clinical laboratory measurements are currently unavailable. Thus, comparisons of biomarker
values between this study and others may be difficult to interpret.
We did not assess detailed neurodevelopmental outcomes and outcomes within the past year,
both of which could potentially enhance the utility of blood-based brain injury biomarkers.
Postresuscitation care, including the use of TTM, was not standardized in this study. Thus, findings
associated with TTM and outcomes should be interpreted with caution. The outcome analysis was
not adjusted for baseline function before cardiac arrest. However, children with baseline Pediatric
Cerebral Performance Category scores of 4 or 5 points were excluded from the study, and the
Pediatric Cerebral Performance Category scale performs similarly to the unfavorable VABS-3
threshold used in this study.42 One-year outcomes were unavailable for 43 children (26.4%) despite
rigorous standard operating procedures and site training, with some notable differences in patient
and hospital characteristics (eTable 6 in Supplement 1). Data regarding do-not-resuscitate status and
deaths occurring after withdrawal of life-sustaining therapies were not collected in this study. The
small sample in this study limited our ability to assess the consequences of coacute conditions such
as sepsis; enrollment of patients with coacute severe brain injury was discouraged.

Conclusions
This cohort study found that blood-based brain injury biomarkers, especially NfL at days 2 and 3 after
cardiac arrest, were associated with the composite outcome of death or unfavorable adaptive
behavior at 1 year after pediatric cardiac arrest with a high degree of accuracy. Evaluation of the
accuracy of the association between these biomarkers and neurodevelopmental outcomes beyond 1
year is needed.
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